Anzeige
Erschienen in:
24.07.2021 | Original Article
Bilateral Orchidectomy Revisited in Management of Metastatic Hormone-Sensitive Prostate Cancer
Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 3/2021
Einloggen, um Zugang zu erhaltenAbstract
Introduction
Androgen deprivation therapy (ADT) is a well-established treatment for metastatic hormone-sensitive prostate cancer (mHSPC). It includes either bilateral orchiectomy or medical castration in form of luteinizing hormone-releasing hormone (LHRH) agonist or antagonist. We conducted this study to compare surgical and medical castration in terms of time to progression (TTP) to castration resistant prostate cancer.
Methods
Patients with mHSPC underwent either bilateral orchidectomy or medical castration by either LHRH agonist or by antagonist from November 2016 to May 2018 in our institution. Initial PSA and baseline imaging either magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET CT) finding were recorded. Serum PSA, testosterone, and FSH were repeated every 3 months till 1 year. All enrolled patients were followed up with a bone scan/MRI/ PET CT at 6 months and 12 months. End point of study was progression of disease and death of patient.
Results
Mean nadir PSA (ng/ml) after treatment was 4.7 and 9.8 in surgical and medical group respectively, whereas mean time to the nadir PSA was 8.7 and 8.8 respectively with no statistically significant difference. Mean TTP was 13.9 months in bilateral orchidectomy group and 13.8 months in medical castration group (chi-square 0.003, p value 0.958).
Conclusion
There was no significant difference in time to progression between bilateral orchidectomy and medical castration. Considering nadir PSA level, better quality of life, patient compliance, reduced hospital visit, and decrease in cost of treatment, bilateral orchidectomy may be a better treatment option especially in developing countries.